Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
25 Nov 2023
25 Nov 2023
Historique:
received:
17
05
2023
accepted:
08
11
2023
medline:
27
11
2023
pubmed:
26
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64
Identifiants
pubmed: 38007484
doi: 10.1038/s41467-023-43553-z
pii: 10.1038/s41467-023-43553-z
pmc: PMC10676398
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7728Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2018 Jun 15;24(12):2859-2872
pubmed: 29602801
Cell. 2013 May 23;153(5):1025-35
pubmed: 23706740
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
J Neuroinflammation. 2022 Jan 6;19(1):6
pubmed: 34991631
Acta Neurol Scand. 2017 Nov;136 Suppl 201:34-36
pubmed: 29068490
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Brain Pathol. 2014 Jan;24(1):83-97
pubmed: 24345222
Eur J Immunol. 2014 Mar;44(3):627-33
pubmed: 24435886
Nat Commun. 2022 Nov 23;13(1):7210
pubmed: 36418303
Mult Scler. 2019 Jul;25(8):1150-1161
pubmed: 29761736
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Blood. 2016 May 5;127(18):2173-81
pubmed: 27002116
Annu Rev Immunol. 2001;19:23-45
pubmed: 11244029
Neurology. 2012 May 15;78(20):1601-7
pubmed: 22551731
Sci Rep. 2019 Dec 19;9(1):19471
pubmed: 31857644
J Exp Med. 2022 Feb 7;219(2):
pubmed: 35015026
Biochem Med (Zagreb). 2011;21(3):282-90
pubmed: 22420242
Nat Immunol. 2010 Aug;11(8):681-8
pubmed: 20644574
Front Immunol. 2017 Dec 11;8:1781
pubmed: 29321780
Immunology. 2005 Nov;116(3):354-61
pubmed: 16236125
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
Nat Immunol. 2011 Sep 11;12(11):1055-62
pubmed: 21909091
J Vis Exp. 2013 Jun 14;(76):e50294
pubmed: 23792786
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):960-971
pubmed: 35835468
Cancer Cell. 2016 Jul 11;30(1):120-135
pubmed: 27374224
F1000Res. 2017 May 26;6:748
pubmed: 28663787
Front Immunol. 2022 Apr 01;13:868915
pubmed: 35432335
Nat Rev Neurol. 2022 May;18(5):289-306
pubmed: 35388213
Neurology. 2009 Jun 2;72(22):1960-1
pubmed: 19487655
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Immunity. 2014 May 15;40(5):785-800
pubmed: 24816404
Blood. 2016 Nov 10;128(19):2327-2337
pubmed: 27609642
Nature. 2015 Sep 24;525(7570):528-32
pubmed: 26374999
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21546-21556
pubmed: 32817525
Expert Rev Mol Diagn. 2005 Mar;5(2):193-207
pubmed: 15833049
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Front Immunol. 2019 Aug 07;10:1883
pubmed: 31440255
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 5;7(3):
pubmed: 32139439
Mult Scler. 2016 Feb;22(2):160-73
pubmed: 26540731
Clin Cancer Res. 2017 Jul 15;23(14):3847-3858
pubmed: 28108544
J Clin Med. 2020 Nov 02;9(11):
pubmed: 33147889
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Front Immunol. 2019 Oct 15;10:2367
pubmed: 31681275
Ann Neurol. 2009 Nov;66(5):630-43
pubmed: 19937948
Cell Syst. 2018 May 23;6(5):612-620.e5
pubmed: 29605184